TY - JOUR
T1 - Ganciclovir treatment of serious cytomegalovirus infection in heart and heart-lung transplant recipients
AU - Keay, Susan
AU - Petersen, Eskild
AU - Icenogle, Timothy
AU - Zeluff, Barry J.
AU - Samo, Tobias
AU - Busch, David
AU - Newman, Cheryl L.
AU - Bühles, William C.
AU - Merigan, Thomas C.
N1 - Funding Information:
This work was supported in part by Syntex Research, which also supplied the ganciclovir, and by grant no. AI 05629-24 from the National Institute of Allergy and Infectious Diseases. Dr. Keay is the recipient of postdoctoral fellowship no. PF-2975 from the American Cancer Society.
PY - 1988/7
Y1 - 1988/7
N2 - Experience with ganciclovir treatment of life-or sight-threatening cytomegalovirus (CM V) infections in 22 heart and heart-lung transplant recipients at six medical centers was reviewed. All six heart-lung recipients and six of 16 heart recipients had CMV pneumonitis; five heart recipients had CMV gastrointestinal disease, three had retinitis, and two had infections in more than one organ system. Of the 18 patients (82%) surviving initial ganciclovir therapy, 16 improved, one stabilized, and one showed no change in clinical status. All cultures positive for CMV before treatment became negative during therapy. Six patients (33% of survivors) had recurrent episodes and received additional therapy. Four patients (18%) died during initial therapy; death was believed to be related to CMV infection in only two cases and to ganciclovir treatment in no case. Adverse reactions possibly attributable to ganciclovir included neutropenia (four patients), impaired renal function (one), thrombocytopenia (one), decreased blood pressure (one), and seizure (one). Ganciclovir appears to be well tolerated and to alter favorably the outcome of serious CMV infection in this patient population.
AB - Experience with ganciclovir treatment of life-or sight-threatening cytomegalovirus (CM V) infections in 22 heart and heart-lung transplant recipients at six medical centers was reviewed. All six heart-lung recipients and six of 16 heart recipients had CMV pneumonitis; five heart recipients had CMV gastrointestinal disease, three had retinitis, and two had infections in more than one organ system. Of the 18 patients (82%) surviving initial ganciclovir therapy, 16 improved, one stabilized, and one showed no change in clinical status. All cultures positive for CMV before treatment became negative during therapy. Six patients (33% of survivors) had recurrent episodes and received additional therapy. Four patients (18%) died during initial therapy; death was believed to be related to CMV infection in only two cases and to ganciclovir treatment in no case. Adverse reactions possibly attributable to ganciclovir included neutropenia (four patients), impaired renal function (one), thrombocytopenia (one), decreased blood pressure (one), and seizure (one). Ganciclovir appears to be well tolerated and to alter favorably the outcome of serious CMV infection in this patient population.
UR - http://www.scopus.com/inward/record.url?scp=0024040720&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024040720&partnerID=8YFLogxK
U2 - 10.1093/clinids/10.Supplement_3.S563
DO - 10.1093/clinids/10.Supplement_3.S563
M3 - Article
C2 - 2847294
AN - SCOPUS:0024040720
SN - 0162-0886
VL - 10
SP - S563-S571
JO - Reviews of Infectious Diseases
JF - Reviews of Infectious Diseases
ER -